Enjoy complimentary customisation on priority with our Enterprise License!
The Stool Testing Market size is estimated to grow by USD 445.95 million, at a CAGR of 5.92% between 2023 and 2028. Market growth is driven by favorable initiatives, the rising prevalence of gastrointestinal diseases, increasing guidelines from healthcare organizations, and the growing incidence of colorectal cancer (CRC). These factors collectively shape market dynamics in the healthcare sector, emphasizing the importance of preventive care, early diagnosis, and treatment innovations. Favorable initiatives include government policies, funding support, and awareness campaigns aimed at improving healthcare outcomes. The increasing prevalence of gastrointestinal diseases, including CRC, underscores the need for advanced diagnostic tools, therapeutic interventions, and personalized treatment options. Healthcare organizations' guidelines and recommendations play a crucial role in standardizing care practices and improving patient outcomes. As these factors converge, the market anticipates growth opportunities driven by innovations in medical technology, pharmaceutical advancements, and a heightened focus on public health initiatives aimed at tackling gastrointestinal diseases and CRC effectively.
For More Highlights About this Report, Download Free Sample in a Minute
The GI segment is estimated to witness significant growth during the forecast period. GI stool testing can be referred to as a diagnosis of digestive tract disorder, which looks for gastrointestinal disorders that appear in the stool. In addition, it utilizes stool cultures to help identify pathogens (bacteria, viruses, microorganisms) present in the GI tract that cause GI distress and other systemic symptoms.
Get a glance at the market contribution of various segments Download the PDF Sample
The GI segment was the largest segment and was valued at USD 643.40 million in 2018. Moreover, some of the findings through GI stool testing include digestion of food, types of bacteria in the gut, presence of dysbiosis, presence of parasites/worms, and strength of the immune system. In addition, some of the various reasons for GI stool testing, include hemorrhoids, peptic ulcers, inflammation in the esophagus, diverticulosis and diverticulitis, ulcerative colitis and Crohn's disease, colonic polyps, or cancer in the colon, stomach, or esophagus. Hence, factors such as the the increasing prevalence of chronic diseases coupled with the growing geriatric population fuels the growth of this segment which in turn drives the market growth during the forecast period.
For more insights on the market share of various regions Download PDF Sample now!
North America is estimated to contribute 40% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period. There has been an increase in the adoption of various advanced technologies for the treatment of GI bleeding in North America over the last few years. In addition, several factors such as the high adoption of technology, increasing prevalence and incidences of GI diseases, growing geriatric population, availability of reimbursement policies for endoscopic procedures, and the growing presence of prominent companies that develop endoscopic devices are significantly contributing to the growth of the market in the region. Furthermore, the increasing prevalence of chronic diseases such as stomach cancer, colon cancer, and pancreatic cancer fuels the need for GI bleeding treatment. Hence, such factors drive market growth in North America during the forecast period.
The test type landscape in healthcare is evolving rapidly to address various conditions, including parasite infection, exacerbated by factors like fast food consumption and stress from today's hectic lifestyle. Amidst rising concerns about gastrointestinal diseases and colorectal cancer, there are pitfalls and challenges such as lack of skilled professionals and stringent regulatory policies impacting GI stool testing. However, advancements in rapid specimen handling and increased automation, exemplified by technologies like Cepheid Xpert and GeneXpert, promise clinical benefits. In this landscape, innovations like ColoClear and insights from research published in journals like PLOS One are pivotal in addressing gastrointestinal disorders and related conditions such as digestive tract diseases, malabsorption, and bowel inflammation. Addressing bleeding obstruction and managing the disease burden require heightened healthcare awareness and effective utilization of healthcare expenditure. As society grapples with the consequences of unhealthy lifestyles, prioritizing preventive measures and efficient diagnostics is paramount for improving overall health outcomes.
One of the key factors driving the market growth is the increasing prevalence of CRC. One of the most common cancers prevailing across the globe is CRC. In addition, several factors that can possibly increase an individual risk of CRC include overweight or obesity, lack of physical activity, smoking, excessive alcohol consumption, unhealthy food intake, personal history of being encountered with colorectal polyps, and inflammatory bowel disease, family history of adenomatous polyps, and type 2 diabetes.
Moreover, certain genetic conditions such as Lynch syndrome, Turcot syndrome, Muir-Torre syndrome, and juvenile polyposis syndrome have significantly increased the risk of CRC and other types of cancer. In addition, to reduce the CRC mortality rate, several screening tests, including FOBT, stool DNA test, flexible sigmoidoscopy, colonoscopy, and imaging scans, are being performed across the world with the help of government and healthcare organizations. Hence, such factors are driving the market growth during the forecast period.
A key factor shaping the market growth is the growing demand for point-of-care testing. The successful reduction in the mortality rates of CRC needs early diagnosis, early initiation of treatment, and accurate screening of individuals who are at risk of CRC. Hence, to perform these tasks, an efficient and sensitive assay is required to increase CRC screening efforts in various healthcare settings.
Moreover, the introduction of POC testing has improved the way diagnostics and clinical procedures are being performed. In addition, early diagnosis and accurate treatment of the disease are the most important strategies implemented by various stakeholders, as early detection of low-grade CRC increases the likelihood of survival, which relies on the patient's age. Therefore, technological advances in the form of low-cost rapid POC tests have transformed the diagnosis and treatment of CRC. Hence, such factors drive the market growth during the forecast period.
High treatment costs associated with GI disorders and colorectal cancer are one of the key challenges hindering market growth. Even though the global market is growing at a rapid pace, the high costs associated with the devices used for diagnoses, such as these kits and treatment of GI bleeding will negatively impact the market, especially in price-sensitive markets such as developing and emerging economies. In addition, even in developed countries, small hospitals and private physician clinics may not opt for endoscopic kits due to budget constraints.
Moreover, endoscopic kits are expensive and classified as capital items by healthcare institutions. In addition, the procurement of endoscopic devices involves many procedures and various budget allocation considerations before making the purchasing decision. Hence, such factors are negatively impacting the market. Therefore, it is expected to hinder the market growth during the forecast period.
Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market.
BioMerieux SA: The company offers stool testing device which is designed to implement sample preparation for nucleic acid extraction of viruses, bacteria, and parasites
The research report also includes detailed analyses of the competitive landscape of the market and information about 15 market companies, including:
Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.
You may also interested in below market reports:
The market is witnessing significant growth due to the rising prevalence of gastrointestinal diseases linked to unhealthy lifestyles. Various test types are available, yet pitfalls and challenges such as a lack of skilled professionals and stringent regulatory policies persist. Advanced GI stool testing tests offer clinical benefits with rapid specimen handling and increased automation, ensuring rapid results in hospital settings. However, challenges like testing procedures, infections, and diagnostic procedures remain. Technologies like Cepheid Xpert and GeneXpert pave the way for improved industry revenue and point-of-care facilities. Despite hurdles like procedure deferral and healthcare costs, the market thrives on product sales driven by the growing burden of gastrointestinal infections. Enhanced healthcare awareness and advancements in FDA-approved instruments further propel business progress in the sector.
Moreover, in today's world, characterized by an unhealthy lifestyle and dietary habits like fast food consumption, the demand for advanced test types for diagnosing various health conditions is on the rise. From conventional diagnostic methods to specialized tests like occult blood, parasites, bacteria, and fecal biomarkers, accurate results hinge upon the operational skills of skilled personnel. This is especially crucial considering the health challenges faced by the baby boomer generation, such as digestive tract bleeding and chronic pancreatitis, contributing to the overall disease burden and escalating healthcare costs.
Further, healthcare professionals strive to improve health-associated quality of life for both men and women, addressing conditions like digestive tract diseases, malabsorption, bowel inflammation, parasite infections, and bleeding obstruction. However, societal factors like stress and hectic lifestyles compound the issue, necessitating efficient healthcare expenditure management. In this landscape, innovative solutions like ColoClear, backed by research published in journals like PLOS One, offer hope for improved diagnostics and management. With a focus on FDA approvals and leveraging the expertise of skilled personnel, the industry aims to address the growing healthcare needs of the population effectively.
|
Market Scope |
|
|
Report Coverage |
Details |
|
Page number |
165 |
|
Base year |
2023 |
|
Historic period |
2018 - 2022 |
|
Forecast period |
2024-2028 |
|
Growth momentum & CAGR |
Accelerate at a CAGR of 5.92% |
|
Market Growth 2024-2028 |
USD 445.95 million |
|
Market structure |
Fragmented |
|
YoY growth 2023-2024(%) |
5.41 |
|
Regional analysis |
North America, Europe, Asia, and Rest of World (ROW) |
|
Performing market contribution |
North America at 40% |
|
Key countries |
US, Canada, UK, Germany, and China |
|
Competitive landscape |
Leading Companies, Market Positioning of Companies, Competitive Strategies, and Industry Risks |
|
Key companies profiled |
AdvaCare Pharma, bioMerieux SA, Cardinal Health Inc., Cenogenics Corp., Danaher Corp., DiaSorin SpA, Eiken Chemical Co. Ltd., Epitope Diagnostics Inc., Exact Sciences Corp., Genova Diagnostics Inc., Helena Laboratories Corp., Hologic Inc., McKesson Corp., Meridian Bioscience Inc., Pinnacle BioLabs, Polymedco CDP LLC, Quest Diagnostics Inc., Quidelortho Corp., CTK Biotech Inc., and ScheBo Biotech AG |
|
Market dynamics |
Parent market analysis, market forecasting, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, Market condition analysis for the market forecast period.. |
|
Customization purview |
If our market report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
We can help! Our analysts can customize this market research report to meet your requirements.
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by Type
7 Market Segmentation by End-user
8 Customer Landscape
9 Geographic Landscape
10 Drivers, Challenges, and Trends
11 Vendor Landscape
12 Vendor Analysis
13 Appendix
Get lifetime access to our
Technavio Insights
Quick Report Overview:
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.
Get the report (PDF) sent to your email within minutes.